Appeal No. 2001-1705 Page 2
Application No. 08/616,141
thereof, in an amount effective to enhance delivery of the
compound to cells preferentially binding the macrocycle, and
b. a pharmaceutically acceptable carrier for pharmaceutical
administration.
Claim 1 is drawn to a method of using the compound-macrocycle mixture.
In addition, various dependent claims further limit the macrocycle to porphyrin,
which may have antiviral activity including, as set forth in claim 26, anti-hepatitis
B activity.
The references relied upon by the examiner are:
Dixon et al. (Dixon) 5,192,788 Mar. 09, 1993
Leonetti et al. (Leonetti) “Antibody-Targeted Liposomes Containing
Oligodeoxyribonucleotides Complementary to Viral RNA Selectively inhibit Viral
Replication,” Proc. Natl. Acad., Sci., Vol. 87 pp. 2448-2451 (1990)
Doan et al. (Doan) “Sequence-Targeted Chemical Modification of Nucleic Acids
by Complementary Oligonucleotides Covalently Linked to Porphyrins,”
Nucleic Acids Research, Vol. 15, No. 21 pp. 8643-8658 (1987)
Korba et al. (Korba) “Use of a Standardized Cell Culture Assay to Assess
Activities of Nucleoside Analogs Against Hepatitis B Virus Replication,”
Antiviral Research, Vol. 19 pp. 55-70 (1992)
Lisziewicz et al. (Lisziewicz) “Specific inhibition of human immunodeficiency virus
type 1 replication b antisense oligonucleotides : An in vitro model for treatment,”
Proc. Natl. Acad. Sci., Vol. 89 pp. 11209-11213 (1992)
Yuan et al. (Yuan) “Targeted Cleavage of mRNA by Human Rnase P,”
Proc. Natl. Acad. Sci, Vol. 89 pp. 8006-8010 (1992)
Cannon, “Pharmaceutics and Drug Delivery Aspects of Heme and Porphyrin
Therapy,” Journal of Pharmaceutical Sciences, Vol. 82,
No. 5 pp. 435-446 (1993)
Offensperger et al. (Offensperger) “In vivo Inhibition of Duck Hepatitis B Virus
Replication and Gene Expression by Phosphorothioate Modified Antisense
Oligodeoxynucleotides,” The EMBO Journal. Vol. 12, No. 3 pp. 1257-1262
(1993)
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 Next
Last modified: November 3, 2007